Cambridge Cognition secures Innovate UK grant for Bio-Hermes 2 project

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to have been selected to provide voice and touchscreen cognitive assessments for the Global Alzheimer’s Platform Foundation’s Bio-Hermes 2 project. Cambridge Cognition is receiving grant funding from Innovate UK, the UK’s innovation agency (as included in the announcement dated 29 May 2024). Three of Cambridge Cognition’s CANTAB™ touchscreen cognitive tasks, measuring working memory, episodic memory and processing speed, and a Winterlight speech and language task will be used.

The Bio-Hermes 2 project aims to generate a world-leading dataset to improve the understanding of how digital and blood-based biomarkers can be used to predict the extent of Alzheimer’s Disease pathology as detected by positron emission tomography (PET) brain scans.  1,200 patients covering the clinical spectrum of the disease, from normal ageing to mild cognitive impairment and through to dementia, will be monitored for up to 24 months.

With such a sizeable sample of patients over a long period, the project will generate a large dataset that will considerably add to the existing scientific evidence for the Company’s voice and touchscreen assessments. In particular, it will be the first large dataset that the Company will have using both CANTAB and Winterlight assessments, providing an opportunity to have combined assessments for patients in the future to better address emerging needs in Alzheimer’s Disease drug development.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, commented:

"We are delighted that our CANTAB and Winterlight solutions will be in the Bio-Hermes 2 project and are grateful to Innovate UK for the funding. This could be a groundbreaking study for Cambridge Cognition, and indeed for the clinical field, as it could enable the company to be the first to provide a combined all-in-one voice and touchscreen assessment for Alzheimer’s disease in the future’.